Longitudinal ctDNA analysis identifies AR gene alterations and extrachromosomal DNA as features of resistanceBlood tests may track how prostate cancer resists treatment

This observational study involved 327 patients with metastatic castration-resistant prostate cancer (mCRPC) who were enrolled in the Alliance A031201 trial. The primary objective was to investigate genomic features of androgen receptor inhibitor (ARPI) resistance through longitudinal ctDNA analysis using a targeted AR-ctDETECT cell-free DNA (cfDNA) sequencing assay performed at baseline and at the time of disease progression.

The study utilized liquid biopsy as a non-invasive method to track molecular changes over time. The primary outcome was the identification of genomic features associated with ARPI resistance. Secondary outcomes included monitoring ctDNA positivity, AR copy-number gains, AR genomic structural rearrangements (AR-GSR), specific copy-number losses (FANCA, POLD1, RAD54L, CDKN2A, ZNRF3, and ETS2), and the presence of an AR extrachromosomal DNA signature.

Key findings from the analysis revealed that ctDNA levels and positivity increased at the point of progression. The androgen receptor (AR) gene was identified as the most frequently altered gene both at baseline and at the time of progression. Specifically, the study observed a significant increase in AR copy-number gains and AR genomic structural rearrangements (AR-GSR) at progression. Furthermore, there was an increased frequency of specific copy-number losses, including FANCA, POLD1, RAD54L, CDKN2A, ZNRF3, and ETS2, at the time of disease progression.

A distinct AR extrachromosomal DNA signature was identified as enriched at progression. This signature was associated with AR-GSRs predicted to truncate the AR ligand-binding domain. The study also differentiated between types of alterations based on progression-free survival: a preferential accumulation of AR alterations was observed in patients with delayed progression, whereas a higher burden of non-AR alterations was noted in patients with rapid progression.

Safety and tolerability data were not reported for this specific analysis. Methodological limitations were not specifically detailed in the provided report. The study results are significant because they highlight how different genomic profiles may correlate with different rates of clinical progression, potentially allowing for more nuanced monitoring of patient response to ARPI therapy.

These findings compare to existing knowledge by providing a molecular map of resistance. While previous studies have established the efficacy of enzalutamide and abiraterone in mCRPC, this study specifically focuses on the genomic mechanisms underlying the failure of these therapies. The identification of specific mutations like those in FANCA or POLD1 provides a deeper look into the biological drivers of resistance.

Clinical implications suggest that liquid biopsy can be a valuable tool for serially tracking resistance mechanisms and may eventually inform precision therapy decisions in advanced prostate cancer. However, because this is an observational study, the association between AR alterations and progression does not establish a direct causal link. Furthermore, the study identifies genomic features of resistance but does not provide a definitive clinical recommendation for specific treatment changes at this time.

Several questions remain unanswered regarding the specific clinical impact of these mutations. It is unclear how frequently these specific ctDNA markers will be used in routine practice to guide immediate treatment pivots. Additionally, more data is needed to determine if identifying these specific genomic signatures can lead to improved outcomes for patients experiencing rapid progression.